Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 553 in FLT3-positive R/R AML
NCT03904069Phase 1Withdrawn
- Sponsor
- Amgen
- Start
- Mar 2023
- Primary completion
- Aug 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMG 553 in acute myeloid leukemia (AML), sponsored by Amgen. Primary endpoints: Dose limiting toxicities at 3 months, Treatment-emergent adverse events at 3 months and 1 more. Planned start Mar 2023; status: withdrawn.
02
Drugs
AMG 553
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03904069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904069.